In a new, proof-of-concept study, pioglitazone has been shown to lessen the metabolic and histologic abnormalities associated with nonalcoholic steatohepatitis (NASH), for which there is currently ...

The Nash Casino officially opened its doors to the public on Wednesday, following a VIP event and ribbon cutting the previous ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.